Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan [PDF]
, 2019 Objectives: To assess whether switching patients with suboptimally controlled pulmonary arterial hypertension from bosentan or ambrisentan to macitentan would improve six-minute walk test (6MWT) distance and World Health Organization functional class ...
Gabbay, Eli +3 more
core +1 more source
Treatment of Cardiovascular Dysfunction With PDE5-Inhibitors - Temperature Dependent Effects on Transport and Metabolism of cAMP and cGMP. [PDF]
Front Physiol, 2021 Selli AL +9 more
europepmc +1 more source
The Sexual Goals of Metoidioplasty Patients and Their Attitudes Toward Using PDE5 Inhibitors and Intracavernosal Injections as Erectile Aids. [PDF]
Sex Med, 2022 Khorrami A +9 more
europepmc +1 more source
Targeting the SARS-CoV-2 3CLpro and NO/cGMP/PDE5 pathway in COVID-19: a commentary on PDE5 inhibitors. [PDF]
Future Cardiol, 2021 Shirvaliloo M.
europepmc +1 more source
Systemic and metabolic effects of PDE5-inhibitor drugs
World Journal of Diabetes, 2010 Phosphodiesterase type-5 inhibitor (PDE5-i) drugs were first marketed in 1998 (sildenafil) for 'ondemand' treatment of male erectile dysfunction (ED) of any origin. They selectively inhibit intrapenile PDE5 isoenzyme which in turn increases intracellular cyclic guanosine monophosphate levels, thus resulting in prolonged relaxation of cavernosum smooth ...
openaire +2 more sources
Tadalafil in the treatment of erectile dysfunction
Therapeutics and Clinical Risk Management, 2008 Robert M Coward, Culley C CarsonDivision of Urologic Surgery, University of North Carolina, Chapel Hill, NC, USAAbstract: The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors ...
Robert M Coward, Culley C Carson
doaj
Inibidores da 5-fosfodiesterase no tratamento sintomático da hiperplasia benigna da próstata [PDF]
, 2011 Trabalho final de mestrado integrado em Medicina, área científica de Urologia, apresentado á Faculdade de Medicina da Universidade de CoimbraTanto a hiperplasia benigna da próstata como a disfunção eréctil são patologias com elevada prevalência em ...
Costa, Christine Silva
core
FIRST-DOSE SUCCESS OF PDE5 INHIBITORS
, 2006 Summary First-dose success of phosphodiesterase type 5 (PDE5) inhibitors may be adversely affected in patients with comorbidities. This article reports first-dose success rates for vardenafil 10 mg in men with erectile dysfunction (ED) and associated comorbidities who participated in the challenge phase of the Reliability – Vardenafil for Erectile ...
F. Montorsi, S. Auerbach, L. Valiquette
openaire +1 more source
PDE5 inhibitors in diabetic peripheral neuropathy.
International journal of clinical practice, 2007 Peripheral neuropathy is the most common complication of diabetes. This paper reviews the case histories of five patients with diabetic peripheral neuropathy or severe peripheral vascular disease who reported improvement in their symptoms when treated with regular or daily dosing with phosphodiesterase type 5 inhibitors (PDE5Is).
openaire +1 more source